Af­ter De­cem­ber tri­al fail, Bridge­Bio has good news from PhII for LGMD2i drug

4 years ago
R&D

No more busi­ness as usu­al: Pfiz­er, Bay­er and Sanofi step up ac­tions against Rus­sia amid grow­ing pres­sure to ex­it

4 years ago
Pharma

FDA or­ders In­cyte to hold up yet again in the hunt for block­buster fran­chise

4 years ago
FDA+

Nek­tar crushed — again — as Bris­tol My­ers al­ly runs in­to PhI­II melanoma fail

4 years ago
R&D

Covid-19 roundup: Mer­ck­'s pill sees heavy use; Mod­er­na faces off against Pfiz­er in vac­cine race for youngest kids

4 years ago
Coronavirus

With a make-or-break PhI­II read­out loom­ing, a strug­gling Con­cert of­floads a 'port­fo­lio' of drugs

4 years ago
Deals

GMP-in-a-box com­pa­ny with Bob Nelsen back­ing lands $167M to de­vel­op its own can­cer drugs

4 years ago
Pharma
Manufacturing

Mov­ing up the treat­ment lines, As­traZeneca clinch­es ad­ju­vant breast can­cer OK for Lyn­parza

4 years ago
Pharma
FDA+

Af­ter first FDA win last year, As­cendis touts a new PhI­II suc­cess in hy­poparathy­roidism

4 years ago
R&D

FDA hits back Fasen­ra in key rhi­nos­i­nusi­tis field, putting As­traZeneca even fur­ther be­hind Big Phar­ma ri­vals

4 years ago
Pharma
FDA+

Sanofi's first big tri­al for top can­cer drug ends in set­back

4 years ago
R&D

Re­vamp com­ing at Gilead; Lat­est from in Ukraine, Rus­sia; Bio­gen’s hang­ing bud­get ax; No­var­tis places gene ther­a­py ...

4 years ago
Weekly

Fre­se­nius cen­ters its own March mad­ness on kid­ney cam­paign with for­mer NBA star and kid­ney trans­plant pa­tient

4 years ago
Pharma
Marketing

Fol­low­ing Vray­lar suc­cess, Ab­b­Vie ex­tends part­ner­ship with Gedeon Richter to neu­ropsy­chi­atric dis­eases

4 years ago
Deals
Pharma

More in­spec­tion trou­ble for Zy­dus just a day af­ter big ac­qui­si­tion

4 years ago
Pharma
Manufacturing

Cal­i­for­nia stem cell clin­ic to pay out $3.65M set­tle­ment to for­mer pa­tients for in­ef­fec­tive treat­ments

4 years ago
Law

Sen­a­tors call on CMS to fi­nal­ize phar­ma­cy fee re­forms to save se­niors $21B in out-of-pock­et ex­pens­es

4 years ago
Pharma
FDA+

US-fund­ed Phlow's first round of es­sen­tial gener­ics head­ed to chil­dren's hos­pi­tals, but they're made with for­eign ...

4 years ago
Pharma
Manufacturing

No­vavax aims for name recog­ni­tion in new vac­cines cam­paign

4 years ago
Pharma
Marketing

South by South­west fes­ti­val re­turns live with cool mu­sic, film de­buts — and a hand­ful of phar­mas

4 years ago
Pharma
Marketing

Pfiz­er com­pletes $6.7B Are­na deal af­ter clock runs out on FTC ob­jec­tion pe­ri­od

4 years ago
Deals

Har­poon cuts bait with lead pro­gram af­ter fail­ing to find sil­ver lin­ings from AS­CO da­ta, oth­er stud­ies

4 years ago
R&D

Covid-19 roundup: Pfiz­er read­ies FDA ap­pli­ca­tion for fourth dose to deal with Omi­cron

4 years ago
Coronavirus

Pfiz­er will not make fu­ture in­vest­ments in Rus­sia but stops short of sev­er­ing all busi­ness ties, Bourla says

4 years ago
People
Pharma
First page Previous page 559560561562563564565 Next page Last page
A service from the Financial Times